Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

View the basic HALO option chain and compare options of Halozyme Therapeutics, Inc. on Yahoo Finance.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Halozyme Therapeutics Inc. stocks have been trading up by 6.57 percent following highly positive news driving strong investor optimism. Key Takeaways A Dutch patent court blocked Merck’s Keytruda SC/QLEX in several major EU markets after finding infringement of Halozyme’s MDASE patent, reinforcing the company’s subcutaneous delivery IP. An expanded global collaboration with argenx adds two…

Halozyme Therapeutics Inc. stocks have been trading up by 6.57 percent following strong sentiment around its key drug pipeline. Key Takeaways A Dutch specialized patent court ruled that Merck’s subcutaneous Keytruda formulation infringes Halozyme’s MDASE patent and ordered a multi‑country

Halozyme Therapeutics Inc. stocks have been trading up by 7.67 percent following highly favorable clinical pipeline advancement news. Key Takeaways A Dutch patent court ruled Merck’s Keytruda SC infringes Halozyme’s MDASE patent and imposed a broad cross‑border injunction across several European markets. The company expanded its global ENHANZE collaboration with argenx, adding new exclusive immunology…

Halozyme Therapeutics Inc. stocks have been trading up by 7.7 percent amid heightened optimism over its latest therapeutic advancements. Key Takeaways A Dutch specialized patent court ruled that Merck’s subcutaneous Keytruda infringes Halozyme’s MDASE patent EP 2,797,622 and issued an injunction

Halozyme Therapeutics Inc. stocks have been trading up by 7.43 percent after upbeat pipeline and partnership progress strengthened investor optimism. Key Takeaways A Dutch specialized patent court ruled that Merck’s subcutaneous Keytruda formulation infringes Halozyme’s MDASE patent EP 2,797,622

Halozyme Therapeutics Inc. stocks have been trading up by 7.43 percent following upbeat sentiment on its oncology pipeline progress. Key Takeaways A Dutch specialized patent court ruled that Merck’s subcutaneous Keytruda infringes a key HALO MDASE patent and ordered an injunction across several European countries, rejecting Merck’s invalidity claims. A separate Dutch injunction blocks manufacture,…